Testing two new medications alone or together for severe bowel inflammation

This trial is testing two new medications called eltrekibart and mirikizumab to see if they can help people with moderate to severe ulcerative colitis—especially those whose disease hasn't responded well to current treatments. You would receive either one medication alone, both medications together, or a placebo (inactive treatment) to compare how well the treatment works. Researchers want to find the best dose and combination to reduce symptoms and improve quality of life.

Many people with ulcerative colitis don't get enough relief from existing medications or develop side effects over time. This medication represents a new approach that works differently than older treatments, and researchers believe combining it with another newer medication could help more patients achieve better control of their disease.